ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Oleuropein- and hydroxytyrosol-loaded nanoparticles: a novel strategy against glioblastoma aggressiveness.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glioblastoma (GB), the most aggressive type of brain tumor, has a poor prognosis. In this study, we aimed to develop a drug delivery system that can be used in GB treatment with the bioactive compounds oleuropein (OL) and its derivative hydroxytyrosol (HT) loaded into mesoporous silica nanoparticles (MSNs) and to investigate their anticancer effects on GB cells. MSNs were synthesized via a sol‒gel method, followed by surface grafting of azetidine to introduce hyperbranched polypropylene imine (PPI) groups, increasing the particle stability and OL/HT loading efficiency. OL and HT-loaded MSN-PPI nanocarriers (MSN-PPI@OL and MSN-PPI@HT) were characterized, and their effects on tumor aggressiveness were evaluated in T98G cells. The results showed that the nanocarriers presented a positive surface charge and hydrodynamic sizes between 300 and 500 nm, with effective concentrations above 100 µg/mL. MSN-PPI@OL and MSN-PPI@HT alone and in combination with temozolomide (TMZ) inhibited cell migration (p < 0.0001), reduced the expression of epithelial‒mesenchymal transition (EMT) markers (p < 0.05), and suppressed angiogenesis (p < 0.0001). In the colony formation assays, the MSN-PPI nanocarriers had stronger antiproliferative effects than did TMZ (p < 0.0001) and suppressed the expression of stem cell markers (p < 0.05). Additionally, these treatments decreased LOXL1-AS1, PVT1, and MALAT1 expression (p < 0.05) and reduced global cell viability (p < 0.0001). In conclusion, these findings suggest the potential of MSN-PPI@OL and MSN-PPI@HT as effective therapeutic strategies for GB.
Indexed as
Identifiers
41020942What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.